- Misinformation #1: Natural immunity offers little protection compared to vaccinated immunity
- Misinformation #2: Masks prevent Covid transmission
- Misinformation #3: School closures reduce Covid transmission
- Misinformation #5: Young people benefit from a vaccine booster
- Misinformation #6: Vaccine mandates increased vaccination rates
- Misinformation #7: Covid originating from the Wuhan Lab is a conspiracy theory
- Misinformation #8: It was important to get the 2nd vaccine dose 3 or 4 weeks after the 1st dose
- Misinformation #8: It was important to get the 2nd vaccine dose 3 or 4 weeks after the 1st dose
- Misinformation #9: Data on the bivalent vaccine is “crystal clear”
- Misinformation #10: One in five people get long Covid
Myocarditis
Browse the articles related to this topic below.
Join our community on Guilded.
Professor Retsef Levi is an MIT Expert in Analytics, Risk Management, Health Systems, Food & Agriculture Systems, Manufacturing & Supply Chain Management.
The evidence is mounting and indisputable that MRNA vaccines cause serious harm including death, especially among young people.
…This is clearly the most failing medical product in the history of medical products, both in terms of efficacy and safety, And we need to investigate. How did we end up in a situation that it’s also the most profitable medical product in the history of medical products?
The pandemic has caused a surge of fatal cardiac arrests in Australia, as delayed care and COVID’s damaging effect on the heart drives a major uptick in serious heart issues.
More than 10,200 Australians died of ischemic heart disease in the first eight months of 2022 – that is about 17 per cent higher than would be expected in a normal year.
Although rare, a statistically significant association between BNT162b2 vaccination and myo/pericarditis and AKI was observed. While the association between BNT162b2 and myo/pericarditis has been confirmed internationally, further research is required to understand the association of AKI. BNT162b2 was not found to be associated with most of the AESIs investigated, providing reassurances around the safety of the vaccine.
https://archive.today/2023.01.23-080922/https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4329970
Joe Langfield, from Kesgrave in Suffolk, died suddenly from an inflammation of the heart muscle called myocarditis in June 2021.
His family said someone at the scene tried to give CPR but Joe was not discovered until too late for his life to be saved. However, they still find it comforting that someone tried to help him.
There are two key points regarding post vaccination heart issues that HART have been raising concerns about since early 2021.
- Myocarditis is attributable to injection not infection
- What has been diagnosed may represent wider harm that is yet to be properly measured
Data from multiple sources now concur on important points. However, there is data from England which appears contradictory.
Dr. John Campbell is an internet sensation, giving facts & data to help us navigate healthcare in the present day. The interview covers John’s development, work, rise to fame & what he would do to help get healthcare back in shape.
A statement from Dr. Joseph Fraiiman, co-author of the study, Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults
The purpose of this study is to determine the ECG parameter change and the efficacy of ECG screening for cardiac adverse effect after the second dose of BNT162b2 vaccine in young population. In December 2021, in cooperation with the school vaccination system of Taipei City government, we performed a ECG screening study during the second dose of BNT162b2 vaccines. Serial comparisons of ECGs and questionnaire survey were performed before and after vaccine in four male-predominant senior high schools. Among 7934 eligible students, 4928 (62.1%) were included in the study. The male/female ratio was 4576/352. In total, 763 students (17.1%) had at least one cardiac symptom after the second vaccine dose, mostly chest pain and palpitations. The depolarization and repolarization parameters (QRS duration and QT interval) decreased significantly after the vaccine with increasing heart rate. Abnormal ECGs were obtained in 51 (1.0%) of the students, of which 1 was diagnosed with mild myocarditis and another 4 were judged to have significant arrhythmia. None of the patients needed to be admitted to hospital and all of these symptoms improved spontaneously. Using these five students as a positive outcome, the sensitivity and specificity of this screening method were 100% and 99.1%, respectively. Conclusion: Cardiac symptoms are common after the second dose of BNT162b2 vaccine, but the incidences of significant arrhythmias and myocarditis are only 0.1%. The serial ECG screening method has high sensitivity and specificity for significant cardiac adverse effect but cost effect needs further discussed. What is Known: • The incidence of cardiac adverse effects was reported to be as high as 1.5 per 10 000 persons after the second dose BNT162b2 COVID-19 vaccine in the young male population based on the reporting system. What is New: • Through this mass ECG screening study after the second dose of BNT162b2 vaccine we found: (1) The depolarization and repolarization parameters (QRS duration and QT interval) decreased significantly after the vaccine with increasing heart rate; (2) the incidence of post-vaccine myocarditis and significant arrhythmia are 0.02% and 0.08%; (3) The serial ECG screening method has high sensitivity and specificity for significant cardiac adverse effect.
https://pubmed.ncbi.nlm.nih.gov/36602621/
Archive link: https://web.archive.org/web/20230000000000*/https://pubmed.ncbi.nlm.nih.gov/36602621/
RESULTS:
Extensive antibody profiling and T-cell responses in the individuals who developed postvaccine myocarditis were essentially indistinguishable from those of vaccinated control subjects, despite a modest increase in cytokine production. A notable finding was that markedly elevated levels of full-length spike protein (33.9±22.4 pg/mL), unbound by antibodies, were detected in the plasma of individuals with postvaccine myocarditis, whereas no free spike was detected in asymptomatic vaccinated control subjects (unpaired t test; P<0.0001).
CONCLUSIONS:
Immunoprofiling of vaccinated adolescents and young adults revealed that the mRNA vaccine–induced immune responses did not differ between individuals who developed myocarditis and individuals who did not. However, free spike antigen was detected in the blood of adolescents and young adults who developed post-mRNA vaccine myocarditis, advancing insight into its potential underlying cause.
Commentary from Wall Street Journal Article: ‘Experts’ Are Fueling Distrust in Vaccines
An article in the American Heart Association’s journal Circulation last week found a link between myocarditis in teens and higher circulating levels of vaccine spike proteins in the blood. The authors found no correlation with vaccine antibody or T-cell responses, suspected by many as the cause of myocarditis.
RNA vaccines are efficient preventive measures to combat the SARS-CoV-2 pandemic. High levels of neutralizing SARS-CoV-2-antibodies are an important component of vaccine-induced immunity. Shortly after the initial two mRNA vaccine doses, the IgG response mainly consists of the pro-inflammatory subclasses IgG1 and IgG3. Here, we report that several months after the second vaccination, SARS-CoV-2-specific antibodies were increasingly composed of non-inflammatory IgG4, which were further boosted by a third mRNA vaccination and/or SARS-CoV-2 variant breakthrough infections. IgG4 antibodies among all spike-specific IgG antibodies rose on average from 0.04% shortly after the second vaccination to 19.27% late after the third vaccination. This induction of IgG4 antibodies was not observed after homologous or heterologous SARS-CoV-2 vaccination with adenoviral vectors. Single-cell sequencing and flow cytometry revealed substantial frequencies of IgG4-switched B cells within the spike-binding memory B-cell population (median 14.4%; interquartile range (IQR) 6.7–18.1%) compared to the overall memory B-cell repertoire (median 1.3%; IQR 0.9–2.2%) after three immunizations. Importantly, this class switch was associated with a reduced capacity of the spike-specific antibodies to mediate antibody-dependent cellular phagocytosis and complement deposition. Since Fc-mediated effector functions are critical for antiviral immunity, these findings may have consequences for the choice and timing of vaccination regimens using mRNA vaccines, including future booster immunizations against SARS-CoV-2.
http://archive.today/2023.01.02-215315/https://www.science.org/doi/10.1126/sciimmunol.ade2798
Something strange is going on with the VAERS system. Reports that were present three months ago are now inexplicably missing. And fewer than 4% of adverse events recorded in V-Safe have made their way to VAERS. This is the CDC’s database; Dr. Rochelle Walensky is in charge of it. And the agency’s failure to properly manage VAERS is suppressing the already-alarming safety signal of the Covid-19 shots.
The vast majority of cases occur in young men, ages 16 to 24, according to the CDC. The agency did not have data available on the total number of cases in young adults 24 and younger, but it estimates there have been 52.4 cases and 56.3 cases per million doses of Pfizer’s and Moderna’s vaccines, respectively.
Symptoms of myocarditis include:
- Chest pain
- Shortness of breath
- Feelings of having a fast-beating, fluttering or pounding heart
A study by Canadian researchers published Monday in the Journal of the American College of Cardiology found that men younger than 40 who got the Moderna vaccine had the highest risk of heart issues, usually within 21 days after the second dose. The study was observational, meaning it doesn’t prove cause and effect but it is one of only a few studies to compare the risk of myocarditis between the Pfizer and the Moderna vaccines.
Conclusion
SARS-CoV-2 vaccination was associated with higher risk of myocarditis death, not only in young adults but also in all age groups including the elderly. Considering healthy vaccinee effect, the risk may be 4 times or higher than the apparent risk of myocarditis death. Underreporting should also be considered. Based on this study, risk of myocarditis following SARS-CoV-2 vaccination may be more serious than that reported previously.
https://www.medrxiv.org/content/10.1101/2022.10.13.22281036v1
From 14 December 2020 through 31 May 2022 (persons 18–39 years) and 20 August 2022 (persons 5–17 years), 320 potential cases of myocarditis/pericarditis were identified 1 to 98 days after 6 992 340 vaccine doses as part of primary series COVID-19 vaccination, with 224 (70%) verified. Of these, 137 (61%) occurred 0 to 7 days after vaccination; 18 were after the first dose (of 3 562 311 doses administered) and 119 were after the second dose (of 3 430 029 doses administered).
In all age groups, incidence per million doses 0 to 7 days after vaccination was numerically higher in male than in female persons and after dose 2, although confidence intervals were wide and overlapped across sex for some age groups. Incidence was highest for male adolescents ages 12 to 15 years and 16 to 17 years following dose 2.
From 24 September 2021 through 20 August 2022, 101 potential cases of myocarditis/pericarditis were identified 1 to 98 days after 1 848 723 first booster doses, with 77 (76%) verified with a median onset of 4.5 days after vaccination; 39 cases (51%) were verified in the first week versus 38 during the subsequent 13 weeks.
In all age groups, incidence 0 to 7 days after first booster was higher for male compared to female persons, with adolescent males having the highest incidence in 16- to 17-year-olds and in 12- to 15-year-olds. In adults for whom both vaccine products were available, post-booster incidence was higher in male than in female adults and higher in males aged 18 to 29 compared to males aged 30 to 39.
http://archive.today/2022.10.06-094825/https://www.acpjournals.org/doi/10.7326/M22-2274
Thousands of American teenagers may have suffered heart inflammation after getting a Covid jab, a study suggests.
Researchers found up to one in 7,000 boys aged 12 to 15 years old developed myocarditis after receiving the Pfizer vaccine.
The condition — which is mild for most but can cause a recurrent heart palpitation in rare cases — was most common after the second dose.
http://archive.today/2022.10.03-220645/https://www.dailymail.co.uk/health/article-11275889/Up-one-7-000-American-teens-suffered-heart-inflammation-Covid-vaccine.html
The risk of myocarditis in this large cohort study was highest in young males after the second SARS-CoV-2 vaccine dose, and this risk should be balanced against the benefits of protecting against severe COVID-19 disease.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2791253
Archive link: https://web.archive.org/web/20230000000000*/https://jamanetwork.com/journals/jamacardiology/fullarticle/2791253
Dr Peter McCullough MD is America’s leading cardiologist and one of its most articulate and fearless sceptics about the official Covid narrative. He talks to James about needless ‘Covid’ deaths, the importance of early treatment, the deliberate suppression of effective cures and his concerns about vaccine side effects, including the increased incidence of myocarditis especially among young men.
Question What is the risk of myocarditis after mRNA-based COVID-19 vaccination in the US?
Findings In this descriptive study of 1626 cases of myocarditis in a national passive reporting system, the crude reporting rates within 7 days after vaccination exceeded the expected rates across multiple age and sex strata. The rates of myocarditis cases were highest after the second vaccination dose in adolescent males aged 12 to 15 years (70.7 per million doses of the BNT162b2 vaccine), in adolescent males aged 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine), and in young men aged 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 vaccine and the mRNA-1273 vaccine, respectively).
Meaning Based on passive surveillance reporting in the US, the risk of myocarditis after receiving mRNA-based COVID-19 vaccines was increased across multiple age and sex strata and was highest after the second vaccination dose in adolescent males and young men.
http://archive.today/2022.08.24-225032/https://jamanetwork.com/journals/jama/fullarticle/2788346
More than thirty doctors, scientists and MP’s have signed a joint letter to the government’s vaccine watchdog urging it to “reassess” the Covid vaccine rollout for healthy 12-15 year olds following new data showing potentially serious harms of the jab are likely to outweigh any potential benefits.
It argues the risk benefit calculations made by the JCVI and the Chief Medical Officer were based on “less than complete data on both the harms and the benefits of vaccinating children compared to the evidence now available.”
It cites new evidence showing the risk of myocarditis in young men and boys is up to 14 times higher after vaccination than after infection.
And it states that given the high level of naturally acquired immunity from infection as well as the replacement of the Delta variant by milder Omicron, “it’s crucial that, if we are to proceed with the mass double vaccination of healthy children, we are absolutely certain this policy will do more good than harm.”
It states that the justification for vaccinating children was to provide “marginal benefits” of reducing time spent out of school due to covid infection but it cites new data showing that vaccines are no longer effective at preventing infection with Omicron.
It states: “Furthermore, the negligible risks of Covid infection to children have become even more nugatory if, as it appears, Omicron is associated with less severe disease, whereas the benefits of natural infection (rather than vaccination) in terms of longer lasting immunity are becoming more clear.”